DiGESTnewborn Study
Launched by CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST · Dec 8, 2019
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The DiGESTnewborn Study is a clinical trial that is looking at how well a mother's blood sugar control during pregnancy affects her baby's blood sugar levels after birth. This study is important because managing blood sugar, especially for mothers with gestational diabetes (a type of diabetes that can occur during pregnancy), can help ensure healthier outcomes for both mothers and their babies.
To participate, mothers and their babies must have already been part of the earlier DiGest Trial and given their consent to join this new study. There are no specific exclusions, which means that most mothers and babies in this situation can take part. If you decide to join, you can expect to help researchers understand how to better manage blood sugar levels during and after pregnancy. This could ultimately lead to improved care for future mothers and their newborns.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • mothers and their babies who have been enrolled in DiGest Trial and who have provided informed consent
- Exclusion Criteria:
- • none
About Cambridge University Hospitals Nhs Foundation Trust
Cambridge University Hospitals NHS Foundation Trust is a leading healthcare organization in the UK, dedicated to advancing medical research and improving patient care through innovative clinical trials. As a prominent academic health science center, it integrates cutting-edge research with clinical practice, fostering collaboration between healthcare professionals, researchers, and patients. The Trust is committed to delivering high-quality, evidence-based healthcare while actively participating in the development of new therapies and interventions aimed at enhancing health outcomes. With a focus on excellence in clinical research, Cambridge University Hospitals aims to translate scientific discoveries into effective treatments, ultimately benefiting the wider community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cambridge, , United Kingdom
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials